Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

The Lancet Oncology
Gilles SallesKami Maddocks

Abstract

Patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for autologous stem-cell transplantation have poor outcomes and few treatment options. Tafasitamab (MOR208) is an Fc-enhanced, humanised, anti-CD19 monoclonal antibody that has shown preclinical and single-agent activity in patients with relapsed or refractory B-cell malignancies. Preclinical data suggested that tafasitamab might act synergistically with lenalidomide. We aimed to assess the antitumour activity and safety of tafasitamab plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma who were ineligible for autologous stem-cell transplantation. In this multicentre, open-label, single-arm, phase 2 study (L-MIND), patients older than 18 years with histologically confirmed diffuse large B-cell lymphoma, who relapsed or had refractory disease after previous treatment with one to three systemic regimens (with at least one anti-CD20 therapy), were not candidates for high-dose chemotherapy and subsequent autologous stem-cell transplantation, had an Eastern Cooperative Oncology Group performance status of 0-2, and had measurable disease at baseline were recruited from 35 academic and community hospitals in ten co...Continue Reading

References

Mar 15, 2006·Immunological Investigations·Scott H OlejniczakMyron S Czuczman
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Jul 9, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter H WiernikThomas M Habermann
Jul 28, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christian GisselbrechtNorbert Schmitz
Jan 14, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T E WitzigM S Czuczman
Jul 25, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jonathan C PoeThomas F Tedder
Feb 26, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T E WitzigM S Czuczman
Jul 21, 2015·Nature Medicine·Wyndham H WilsonLouis M Staudt
Jul 22, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John G GribbenFranck Morschhauser
Sep 13, 2016·CA: a Cancer Journal for Clinicians·Lauren R TerasChristopher R Flowers
Dec 4, 2016·Hematology·Bertrand Coiffier, Clémentine Sarkozy
Apr 7, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Myron S CzuczmanIan D Lewis
Dec 12, 2017·The New England Journal of Medicine·Sattva S NeelapuWilliam Y Go
Dec 7, 2018·The New England Journal of Medicine·Stephen J SchusterUNKNOWN JULIET Investigators
Nov 7, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Brad S KahlOwen A O'Connor
Nov 7, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laurie H SehnMatthew J Matasar

❮ Previous
Next ❯

Citations

Sep 17, 2020·Expert Opinion on Biological Therapy·Christian KleinTina Nielsen
Sep 19, 2020·Drugs·Sheridan M Hoy
Oct 27, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel O PerskyJonathan W Friedberg
Dec 3, 2020·Vaccines·Robert PytlikPavel Klener
Dec 5, 2020·Hematology·Sonali Smith
Dec 5, 2020·Hematology·Kami Maddocks
Dec 10, 2020·Expert Opinion on Investigational Drugs·Andrea Patriarca, Gianluca Gaidano
Jan 13, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alvaro J Alencar, Craig H Moskowitz
Jan 19, 2021·MAbs·Hélène Kaplon, Janice M Reichert
Nov 2, 2020·Molecular Therapy : the Journal of the American Society of Gene Therapy·Mark B LeickMatthew J Frigault
Feb 9, 2021·Expert Opinion on Biological Therapy·Gilles SallesWojciech Jurczak
Nov 19, 2020·International Journal of Molecular Sciences·Leonard Jeff HarrisMichael Martin
Jan 21, 2021·Cancers·Matthew J Olnes
Nov 13, 2020·Expert Review of Hematology·Ruth Alonso-AlonsoMiguel A Piris
Dec 17, 2020·Life·Valentina GiudiceCarmine Selleri
Dec 29, 2020·Journal for Immunotherapy of Cancer·Sattva S NeelapuMichael R Bishop
Jan 1, 2021·Case Reports in Transplantation·Iuliana VaxmanMorie A Gertz
Mar 4, 2021·The New England Journal of Medicine·Laurie H Sehn, Gilles Salles
Mar 27, 2021·American Society of Clinical Oncology Educational Book·Harsh ShahKami Maddocks
Apr 7, 2021·Blood Cancer Journal·Bruce D ChesonGilles Salles
Apr 18, 2021·Naunyn-Schmiedeberg's Archives of Pharmacology·Gizem Kayki-Mutlu, Martin C Michel
Apr 22, 2021·Journal of Hematology & Oncology·Jing-Zhou HouDelong Liu
Jan 25, 2021·Clinical Lymphoma, Myeloma & Leukemia·Brian G BazzellVictoria R Nachar
May 14, 2021·Blood·Andrew McMillan
May 15, 2021·The Lancet Oncology·Kami Maddocks
May 28, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ashley E RoskoHeidi D Klepin
Jun 4, 2021·Journal of Translational Medicine·Paolo A AsciertoIgor Puzanov
May 28, 2021·Biologics : Targets & Therapy·Mattia NovoUmberto Vitolo
May 22, 2021·Cancer Management and Research·Thomas A Ollila, Adam J Olszewski
Jun 7, 2021·Journal of Hematology & Oncology·Yurou ChuXin Wang
Jul 2, 2021·Journal of Hematology & Oncology·Walter Hanel, Narendranath Epperla
Jul 16, 2021·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Geoffrey Shouse, Alex F Herrera

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

B cell Activation

B cell activation is initiated by the ligation of the B cell receptor with antigen and ultimately results in the production of protective antibodies against potentially pathogenic invaders. Here is the latest research.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.